Navigation Links
Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
Date:1/8/2009

FRAZER, Pa., Jan. 8 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that Frank Baldino, Jr., Ph.D., Chairman and CEO will present at the J.P. Morgan Healthcare Conference, to be held on January 13, 2009 in San Francisco, CA at approximately 4:00 p.m. Pacific Time (7 p.m. Eastern Time). The presentation will be webcast live on the investor relations section of the company's website.

The webcast will be archived for one week following the broadcast. To access the webcast, log on to the company's website at www.cephalon.com and click on "Investors," then "Webcast." Click on the link and follow the prompts for registration and access.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in three core therapeutic areas: central nervous system, pain, and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), TREANDA(R) (bendamustine hydrochloride) for Injection, FENTORA(R) (fentanyl buccal tablet) [C-II], PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(R) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
2. Wyeth to Present at the JP Morgan Healthcare Conference
3. VNUS Medical Technologies to Present at 27th Annual J.P. Morgan Healthcare Conference
4. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
5. Warner Chilcott to Present at the 27th Annual JP Morgan Healthcare Conference
6. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
7. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
8. Digirad Corporation CEO to Present at J.P. Morgan Healthcare Conference in San Francisco
9. Insulet Corporation to Present at the J.P. Morgan Healthcare Conference on January 14, 2009
10. Stryker To Present at Investor Conference
11. Immunomedics to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... Thank you to all who attended Capio Partners Winter 2017 Healthcare Leadership Symposium in ... and offered an opportunity to collaborate and network with healthcare colleagues across the United ... gathered for a lively discussion on trends and issues that healthcare leaders will face ...
(Date:3/28/2017)... ... ... that reveals the mystery of Kevin’s purpose. “A Prophets Bones” is the creation of published ... him that he had neglected to do, but this was from God and there was ... would have felt themselves to be special and better than others due to the fact ...
(Date:3/27/2017)... ... ... New patients who have sleep apnea in Aurora, CO, can now ... Sleep apnea is often left untreated because patients are not familiar with common symptoms ... , Dr. Braasch seeks to raise awareness of sleep apnea in Aurora, CO, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Bruce Trimble and Michelle ... requiring a referral. Trimble Dental offers a variety of services to meet each ... Whether patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. ...
(Date:3/27/2017)... ... ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and Bilal Chaudhry ... this treatment plays in protecting oral health, along with the benefits of receiving ... a root canal in White Plains, NY or their second location in Mt. Kisco, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017  BERG, a biopharmaceutical ... biological research approach, today announced that the ... discovery of new data using a cold-induced ... fat metabolism. Joslin Diabetes Center led the ... platform for analysis of samples.  The findings ...
(Date:3/27/2017)... , March 27, 2017  iCAD (Nasdaq: ... workflow solutions and radiation therapy for the early ... PowerLook® Tomo Detection received Premarket Approval (PMA) from ... Tomo Detection is a first-of-its-kind, concurrent-read computer aided ... is the latest innovation available on the PowerLook® ...
(Date:3/27/2017)...  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its ... as Impax,s President and Chief Executive Officer and ... 2017. Mr. Bisaro will succeed J. Kevin Buchi ... Executive Officer since December of 2016. ... Mr. Bisaro, 56, is an accomplished global business leader ...
Breaking Medicine Technology: